This brand name is authorized in Austria, Germany, Turkey
The drug INSIDON contains one active pharmaceutical ingredient (API):
|
1
Opipramol dihydrochloride
UNII B49OBI656M - OPIPRAMOL HYDROCHLORIDE
|
|
Opipramol has high affinity for the sigma binding sites (type 1 and type 2) and has an antagonistic effect at the type 1 histamine receptors. The affinity for the type 2A serotonin receptors, type 2 dopamine receptors and the α-adrenergic receptors is lower. In contrast to the structurally related tricyclic antidepressants, opipramol has only slight anticholinergic activity and does not inhibit the reuptake of serotonin or noradrenaline. In humans, opipramol has sedating, anxiolytic and slight mood-elevating effects. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AA05 | Opipramol | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AA Non-selective monoamine reuptake inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: DE | Bundesinstitut für Arzneimittel und Medizinprodukte | Identifier(s): 01755255, 02410481, 02410498 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699586120060 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
